Antimicrobial peptides (AMPs), molecules evolutionarily conserved among various species, are usually positively charged, having both hydrophobic and hydrophilic domains. They are also called host defense peptides (HDPs), because they participate in the innate immune response by exerting antimicrobial activities against Gram-negative and -positive bacteria, viruses and fungi. Moreover, some HDPs (such as human cathelicidin peptide LL-37 and guinea pig cathelicidin CAP11) directly bind with Gram-negative bacterial endotoxin (lipopolysaccharides, LPS) and neutralize its biological activity 1) -5) . Based on their potent and broad spectrum of activities, they are expected to become novel therapeutic agents. In fact, HDP derivatives are being developed as antibiotics, anti-inflammatories and antifungals. In addition to their direct antimicrobial properties, HDPs have the ability to enhance immunity and link innate and adaptive immunity by functioning as immunomodulators.
There are two major families of HDPs, defensins and cathelicidins. Defensins are small cysteine-rich cationic peptides consisting of 18-45 amino acids, and include six to eight conserved cysteine residues with intramolecular disulfide bonds. Defensins are found in both vertebrates and invertebrates (including arthropods), and also in plants. In contrast, cathelicidins are characterized by a highly conserved Nterminal cathelin-domain, and a variable C-terminal antimicrobial peptide domain (12-80 amino acid residues). Cathelicidin peptides have been isolated from many different mammalian species.
In this issueʼs Current Topics, findings about the "Current status and future perspective on the application of host defense peptides to medicine"are reviewed. First, Dr. Hu demonstrated LL-37 to be a promising candidate for sepsis, based on its potential abilities, including the inhibition of pyroptosis (a recently identified caspase-1 dependent macrophage cell death pathway), and modulation of inflammatory cytokine production and antimicrobial activity. Second, Dr. Suzuki suggests the possibility that during sepsis (endotoxemia) LL-37 may not only suppress LPS-induced endothelial cell apoptosis through the inhibition of LPS-binding to the cells but also induce the clearance (uptake) of LPS by endothelial cells via complex formation with LPS. Third, Dr. Ishibashi characterizes insect (beetle) defensin-derived AMPs, and demonstrates their therapeutic applications to bacterial infections and their use as novel antimicrobial materials such as AMP-immobilized fibers. Furthermore, Dr. Niyonsaba reviews the roles of HDPs in human skin diseases, based on their antimicrobial and immunomodulatory actions in the skin. By understanding the roles of HDPs in the pathophysiology of skin diseases, novel therapeutic targets can be identified, and potential treatments can be developed for these skin conditions. Lastly, Dr. Tamura reviews the Limulus amoebocyte lysate (LAL) test, which is the most sensitive and reliable assay for the detection of trace amounts of bacterial endotoxin (LPS); thus, the LAL test can be utilized for the diagnosis of sepsis, or endotoxemia. However, it is important to note that the LAL test can be affected by the presence of HDPs, since HDPs with potent LPS-neutralizing activities (such as LL-37 and CAP11) can mask the endotoxin active site when they bind. Interestingly, LAL is prepared from amoebocytes (hemocytes) of horseshoe crabs ( Figure-1A and B). Horseshoe crab hemocytes contain two types of granules; large granules contain the essential components of the LAL test, including serine protease zymogens (factor C, factor G and factor B), proclotting enzyme and the clotting factor coagulogen, whereas small (dense) granules contain AMPs 6) . 
